Brief: BCAL Diagnostics Clarifies Of Bcal's Position In Relation To Genetic Signatures
10/09/2026 08:51
BRIEF-BCAL Diagnostics Clarifies Of Bcal's Position In Relation To Genetic Signatures Sept 10 (Reuters) - BCAL Diagnostics Ltd BDX.AX:
CLARIFICATION OF BCAL'S POSITION IN RELATION TO GENETIC SIGNATURES
COMMENTS ATTRIBUTED IN ARTICLE REFER TO VIEWS OF SOME FUND MANAGERS WHO HAVE BEEN ADVOCATING FOR A THREE-WAY MERGER
COMMENTS WERE NOT MADE ON BEHALF OF BCAL
CONFIRMS NOT MADE OR RECEIVED ANY PROPOSAL AND NOT IN DISCUSSIONS WITH GSS OR MAP FOR MERGER OR OTHER COMBINATION
Further company coverage: BDX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BCAL Diagnostics
See all newsAustralia's Genetic Signatures urges largest stakeholder to clarify merger intentions; shares rise
Brief: BCAL Diagnostics Introduces Avantect Multi-Cancer Early Detection Test
Brief: BCAL Diagnostics Clarifies Of Bcal's Position In Relation To Genetic Signatures
Brief: Genetic Signatures Requested BCAL Diagnostics To Clarify Details Of Shareholdings, Associates In Co
Brief: BCAL To Acquire Shares In Genetic Signatures